CSI Market
Sign In | Register

Amicus Therapeutics inc (FOLD) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access FOLD Annual Cash Flow →
By examining cash flow figures across successive periods, users can identify shifts in Amicus Therapeutics inc's cash generation and deployment strategy.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Sep 30 2025) (Jun 30 2025) (Mar 31 2025) (Dec 31 2024)
Operating Activities
Income-27.11
Depreciation & amortization7.46
Amortization of Other Assets2.57
Increase (Decrease) in Deferred Revenue0.00
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories-111.48
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets, Total0.00
Share-based Compensation87.41
Income (Loss) from Equity Method Investments0.00
Gains (Losses) on Extinguishment of Debt0.00
Share Based Goods And Nonemployee Services Transaction Expense-
Change In Fair Value Of Warrant Liability Adjustments To Reconcile Net Loss To Net Cash Used In Operating Activities-
Stock Based License Payments-
Fair Value Net Derivative Asset Liability Measured On Recurring Basis Change In Unrealized Gain Loss-
Research Expense For Stock Issuance In Asset Acquisition-
Noncash Income Tax Expense Benefit-
Increase Decrease In Noncurrent Operating Liabilities-4.34
Research Expense For Asset Acquisition-
Asset Impairment Charges And Other Asset Write Offs7.21
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable-5.86
Increase (Decrease) in Accounts Payable and Accrued Liabilities82.78
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-1.38
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities3.59
Discontinued operations0.00
Net Cash flow from Operating Activities33.15
Investing Activities
Capital Expenditures-3.30
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Available-for-sale Securities51.27
Payments to Acquire Marketable Securities-94.41
Payments for Tenant Improvements0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Payments to Acquire Businesses, Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-46.43
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock19.21
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-18.32
Proceeds From Exercise Of Warrants Common And Preferred-
Payments For Repurchase Of Restricted Stock Units-
Payment Of Contingent Consideration-
Premiums Paid For Capped Call Confirmations-
Finance Lease Principal Payments-0.04
Proceeds From Issuance Of Warrants And Equity Financing-
Proceeds From The Issuance Of Shares In Connection With At The Market Offering Net Of Issuance Costs-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities0.61
Effect of exchange rate on cash flow13.28
Discontinued operations0.00
Free Cash Flow29.85
Total Cash Flow0.60
4 historic quarters locked

Sign in to unlock the full Amicus Therapeutics inc cash flow history.

Sign In Create Free Account

About Amicus Therapeutics Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001178879-25-000015

Figures are derived from filed reports and may be restated. Historical data is subject to revision.